Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer

NARecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 1, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Lung Neoplasm Malignant

Interventions

DRUG

sintilimab

Sintilimab 200 mg, 4 cycles of treatment before surgery

DRUG

bevacizumab

bevacizumab 15 mg/kg, 4 cycles of treatment before surgery

Trial Locations (1)

RECRUITING

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors

lead

Ruijin Hospital

OTHER